236 related articles for article (PubMed ID: 21988567)
1. Association of cinacalcet adherence and costs in patients on dialysis.
Lee A; Song X; Khan I; Belozeroff V; Goodman W; Fulcher N; Diakun D
J Med Econ; 2011; 14(6):798-804. PubMed ID: 21988567
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
[TBL] [Abstract][Full Text] [Related]
3. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.
Gincherman Y; Moloney K; McKee C; Coyne DW
Hemodial Int; 2010 Jan; 14(1):68-72. PubMed ID: 19732171
[TBL] [Abstract][Full Text] [Related]
4. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
6. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
7. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
Belozeroff V; Lee A; Tseng S; Chiroli S; Campbell JD
J Med Econ; 2013 Sep; 16(9):1154-62. PubMed ID: 23869940
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
Komaba H; Moriwaki K; Goto S; Yamada S; Taniguchi M; Kakuta T; Kamae I; Fukagawa M
Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709
[TBL] [Abstract][Full Text] [Related]
9. Medicaid beneficiaries with congestive heart failure: association of medication adherence with healthcare use and costs.
Esposito D; Bagchi AD; Verdier JM; Bencio DS; Kim MS
Am J Manag Care; 2009 Jul; 15(7):437-45. PubMed ID: 19589011
[TBL] [Abstract][Full Text] [Related]
10. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.
Oleen-Burkey MA; Dor A; Castelli-Haley J; Lage MJ
J Med Econ; 2011; 14(6):739-47. PubMed ID: 21913796
[TBL] [Abstract][Full Text] [Related]
11. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
12. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence, healthcare costs and utilization associated with acne drugs in Medicaid enrollees with acne vulgaris.
Tan X; Al-Dabagh A; Davis SA; Lin HC; Balkrishnan R; Chang J; Feldman SR
Am J Clin Dermatol; 2013 Jun; 14(3):243-51. PubMed ID: 23572294
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
16. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Borah B; Sacco P; Zarotsky V
Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Schumock GT; Walton SM; Lee TA; Marx SE; Audhya P; Andress DL
Nephron Clin Pract; 2011; 117(2):c151-9. PubMed ID: 20699620
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States.
Boer R; Lalla AM; Belozeroff V
J Med Econ; 2012; 15(3):509-20. PubMed ID: 22313328
[TBL] [Abstract][Full Text] [Related]
19. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis.
Adeyemi AO; Rascati KL; Lawson KA; Strassels SA
Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712
[TBL] [Abstract][Full Text] [Related]
20. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
